Background
Idiopathic pulmonary fibrosis (IPF) is often associated with elevations in pulmonary artery pressures. Although primary pulmonary arterial hypertension (PAH) has been associated with primary graft dysfunction (PGD), the role of secondary PAH in mediating PGD risk in patients with IPF is incompletely understood. The purpose of this study was to evaluate the relationship between mean pulmonary artery pressure (mPAP) and PGD among patients with IPF.
Methods

We performed a multicenter prospective cohort study of 126 lung transplant procedures performed for IPF between March 2002 and August 2007. The primary outcome was grade 3 PGD at 72 h after lung transplant. The mPAP was measured as the initial reading following insertion of the right-sided heart catheter during lung transplant. Multivariable logistic regression was used to adjust for confounding variables.
Results
The mPAP for patients with PGD was 38.5 ± 16.3 mm Hg vs 29.6 ± 11.5 mm Hg for patients without PGD (mean difference, 8.9 mm Hg [95% CI, ; P = .001). The increase in odds of PGD associated with each 10-mm Hg increase in mPAP was 1.64 (95% CI, P = .003) . In multivariable models, this relationship was independent of confounding by other clinical variables, although the use of cardiopulmonary bypass partially attenuated the relationship.
Conclusions
Higher mPAP in patients with IPF is associated with the development of PGD. Idiopathic pulmonary fibrosis (IPF) is a fatal and chronically progressive diffuse parenchymal lung disease that is characterized by varying degrees of fibrosis of the lung parenchyma. [1] Currently, there are few proven, standardized therapies for IPF [2] ; the only viable treatment that has shown survival benefit for patients with advanced stages of IPF is lung transplantation. [3] , [4] , [5] , [6] , [7] Nonetheless, the survival benefit for lung transplantation in patients with IPF is still complicated by significant early mortality rates, especially within the first year (approximately 28%). The 10-year survival rate after lung transplantation is worse for patients with IPF when compared with other diseases, such as idiopathic pulmonary arterial hypertension (PAH), cystic fibrosis, and ɑ 1 -antitrypsin-deficiency emphysema. [8] Elevated mean pulmonary arterial pressure (mPAP) in patients with IPF has been associated with decreased exercise capacity and worse survival. [9] Higher mPAP was also associated with increased mortality following lung transplantation in a large registry study. [10] One possible explanation for the link between PAH and early mortality after lung transplantation is primary graft dysfunction (PGD), a severe, acute lung injury occurring early after lung transplantation that is responsible for significant morbidity and mortality. [ Figure 1 Study flow diagram by pulmonary arterial hypertension (PAH) and primary graft dysfunction (PGD) status after lung transplantation. An mPAP of > 40 mm Hg indicated the presence of PAH; an mPAP of ≤ 40 mm Hg indicated that PAH was not present. BLT = bilateral lung transplantation; IPF = idiopathic pulmonary fibrosis; mPAP = mean pulmonary arterial pressure; SLT = single-lung transplantation.
Abbreviations
Study subjects had organ preservation and underwent postoperative immunosuppression according to local protocols. Sites during the cohort period were nearly uniform in using low-potassium, extracellular-type preservation fluid. Immunosuppression included induction with IL-2 receptor antagonists at all but one site, followed by maintenance using a calcineurin inhibitor, azathioprine or mycophenolate mofetil, and steroids.
Risk Factor and Outcome Variables
The primary outcome was grade 3 PGD recorded at 72 h, defined by the presence of radiographic infiltrates consistent with pulmonary edema and a PaO 2 /FIO 2 ratio of < 200. [11] , [12] , [14] , [20] The primary risk factor was mPAP, reported from initial reading during right-sided heart catheterization performed in the operating room. The mPAP was assessed as a continuous variable. Donor, recipient, and intraoperative variables were evaluated for potential confounding effects on the relationship of the mPAP and PGD. Potentially confounding variables included donor and recipient age, sex, and race; procedure type (single lung vs bilateral); presence of cardiopulmonary bypass; use of nitric oxide; ischemic time; the study center; and the amount of packed RBCs, platelets, and fresh frozen plasma used during the lung transplant procedure. Cardiac output data were not collected prospectively; however, in post hoc analyses, we reviewed charts at a single institution (University of Pennsylvania) to retrospectively collect cardiac output data. These analyses are reported separately. Sensitivity analyses were performed using any grade 3 PGD occurring at grading times during the first 3 days following surgery (T24-T72) as the outcome.
Statistical Analysis
Continuous data were reported as mean values and SDs, while categorical data were presented as counts and percentages. Univariate associations were tested for significance using χ 2 or exact tests for discrete variables, as well as the Student t test (for approximately normal data). The relationship of mPAP and predicted probability of PGD was graphed using a fractional polynomial fit.
Multivariable logistic regression was used to adjust for potential confounding variables. Confounding variables introduced into the multivariable model one at a time in order to prevent model overfitting. Confounding was defined as a change in the OR of 15% or greater on adjustment. The Pearson goodness-of-fit test was used for postestimation fit of the logistic model. Center effects were accounted for using a robust variance estimator for cluster-correlated data. All statistical comparisons were performed using STATA version 10.1 (StataCorp; College Station, Texas) and SAS version 9.1 (SAS Institute; Cary, North Carolina).
A total of 480 patients were enrolled, and IPF was diagnosed in 154 of these patients. Twenty-eight patients were excluded because of missing mPAP data (e-Table 1). A total of 126 patients with IPF who underwent either SLT or BLT were included in the overall study population (Fig 1) . Table 1 presents baseline donor, preoperative recipient, and intraoperative recipient characteristics among subjects with IPF according to PGD status. Twenty-nine patients (23%) met the criteria for PGD. Black subjects tended to have a slightly greater risk of PGD. Patients with PGD had higher pulmonary artery systolic and diastolic pressures, required larger volumes of packed RBCs, and were more likely to have undergone cardiopulmonary bypass. However, there was no detected difference in the use of intraoperative nitric oxide for patients with or without PGD. Data are shown as means with 95% CIs or as percentages. IPF = idiopathic pulmonary fibrosis; PGD = primary graft dysfunction.
The relationship of mPAP as a continuous variable with PGD among patients with IPF is depicted in Figure 2 . The mPAP was higher in patients who developed PGD at 72 h: 38.5 ± 16.3 mm Hg in patients with PGD vs 29.6 ± 11.5 mm Hg in patients without PGD (mean difference, 8.9 mm Hg [95% CI, 3.6-14.2]; P = .001). The increase in odds of grade 3 PGD for each 10-mm Hg increase in mPAP was 1.64 (95% CI, 1.18-2.26; P = .003). In multivariable models, this relationship was independent of all clinical variables, although the use of cardiopulmonary bypass attenuated the relationship (Table 2) . In a multivariable model simultaneously adjusting for the use of cardiopulmonary bypass and red cells transfused intraoperatively, the relationship of mPAP with PGD maintained borderline significance (OR, 1.41 [95% CI, 1.00-1.99]; P = .053). The Pearson goodness-of-fit test showed that both the base and multivariable logistic models fit the data reasonably well (P = .363 and P = .282, respectively). ORs listed are for the risk of PGD for each 10 mm Hg increase in mPAP, adjusted individually for each confounding variable. mPAP = mean pulmonary arterial pressure. See Table 1 for expansion of other abbreviations.
The mortality rates at both 30 days and 90 days for patients with severe PAH (13% and 17%, respectively) appeared greater compared with those of patients without PAH (3% and 5%). However, these results did not achieve statistical significance:
The 30-day relative mortality risk was 4.27 (95% CI, 1.01-18.00; P = .055), and the 90-day relative mortality risk was 3.2 (95% CI, 0.99-10.31; P = .057).
The association of mPAP and PGD was similar in the 63 subjects who underwent BLT (OR per 10-mm Hg increase, 1.69 [95% CI, 1.12-2.55]; P = .012) and the 63 patients who underwent SLT (OR per 10-mm Hg increase, 1.46 [95% CI, 0.83-2.57]; P = .19). There was no effect modification on multiplicative interaction testing in the logistic model (P = .53).
In post hoc analyses of cardiac output data, 56 of the 70 patients at the University of Pennsylvania had cardiac outputs recorded. In this subpopulation, 10 subjects had PGD at 72 h. The mean cardiac output among patients with PGD was 5.0 ± 1.8 L/min vs 5.8 ± 2.6 L/min in patients without PGD (mean difference, 0.9 L/min [95% CI, -0.9 to 2.6]; P = .32). The effect of mPAP on PGD risk within this subpopulation was similar to that of the overall group, with an OR of 1.55 for each 10-mm Hg increase in mPAP (95% CI, 0.91-2.65; P = .11), and there was no significant confounding of this relationship by cardiac output (adjusted OR, 1.47 [95% CI, 0.85-2.95]; P = .17).
When sensitivity analyses were performed for the 43 patients (34%) who met the criteria for any grade 3 PGD at any time point between T24 and T72, the mPAP remained associated with PGD (OR per 10-mm Hg increase, 1.33 [95% CI, 1.00-1.77]; P = .048). However, this relationship did not maintain independence when adjusted for the use of blood products or cardiopulmonary bypass.
We have demonstrated a strong clinical association between higher mPAP and the risk of PGD among subjects with IPF. The multicenter nature of the study, prospective data collection, and relatively short period of data collection make these findings applicable to the general lung-transplant population.
PAH is common among patients with IPF who are undergoing lung transplantation, [24] and previous research has implicated PAH in the risk of PGD. [12] , [14] , [21] , [25] Recently, Whitson et al [21] demonstrated that increased preoperative mPAP is an independent risk factor for the development of grade 3 PGD within the first 48 h after transplant. Our study adds to these findings by specifically evaluating secondary PAH in patients with IPF in a multicenter prospective cohort study designed to study PGD. The mechanistic underpinnings of the increased risk of PGD among patients with IPF and PAH include greater endothelial injury from hemodynamic forces in addition to inherent abnormalities in coagulation /inflammation, platelet activation, and cell adhesion observed in transplant recipients with both elevated mPAP and PGD. [22] , [23] , [26] Furthermore, vasoactive mediators such as endothelin-1, platelet-derived growth factor, transforming growth factor-β, and fibroblast growth factor have all been implicated in the pathogenesis of IPF, and these mediators can also contribute to the development of lung injury. [27] , [28] , [29] , [30] In addition to raising questions about the shared pathophysiologic characteristics of secondary PAH and PGD, our study may have direct clinical implications. Knowledge of elevated mPAP as an independent risk factor for PGD in patients with IPF may help in counseling patients and families on the risks of transplantation. In addition, the identification of higher-risk patients may eventually lead to trials of selective treatment for patients prior to the development of PGD, perhaps with vasoactive or antiplatelet agents. Importantly, given that IPF is often fatal in the absence of lung transplantation, our results should not be interpreted as evidence to exclude certain groups of patients from lung transplantation.
Our study has several limitations. In this study, the individual effects of cardiopulmonary bypass, use of blood products, and PAH cannot be delineated since they often are apparent in the same patients. In particular, the primary reason for the use of cardiopulmonary bypass (eg, planned or urgent) was not recorded in this study. Additionally, there is potential for bias in the measurement of intraoperative mPAP. Although our goal was to record the measurement of mPAP prior to anesthesia induction, the exact timing of the measurement can be inaccurate and thus can reflect variability in the amount of induction, volumes, and sedation. Other hemodynamic details and measurements during right-sided heart catheterization, such as pulmonary capillary wedge pressure, cardiac output, and FIO 2 at the time of catheter insertion were not routinely measured in the subjects in this cohort study. [31] Measurements of mPAP can vary with right-sided heart function and volume status. Other measures of pulmonary hypertension, such as pulmonary vascular resistance, were not evaluated because pulmonary capillary wedge pressures are not routinely recorded in the operating room. Our post hoc analyses of cardiac output were limited by these missing recorded data and did not have adequate power. Nonetheless, these analyses did not reveal significant confounding of the relationship of mPAP with PGD.
The present study demonstrates the importance of elevated mPAP in patients with IPF as a risk factor for the development of PGD. Future studies are needed to help explain the pathogenic link between PAH and PGD. Furthermore, these results may help in identifying patients with IPF who are at greater risk for PGD prior to lung transplantation.
